You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
次新異動 | 歷時5個月新冠藥物取得進展,開拓藥業尾盤暴力上漲超40%
uSMART盈立智投 12-14 16:07

uSMART盈立智投12月14日消息,次新股開拓藥業-B股價強勢,早盤漲幅維持在11%左右,午後股價繼續發力,尾盤更是暴力拉昇,高見13.86港元,漲幅42.3%,創今年5月上市以來單日最大漲幅。不過該股上市以來的累計跌幅仍然超過30%。

消息面上,開拓藥業-B上週五公佈了其在巴西進行的普克魯胺治療COVID-19的臨牀試驗最新突破進展。初步結果顯示,普克魯胺可能通過降低TMPRSS2和ACE-2表達,顯著減少COVID-19患者自輕症到重症的惡化。該臨牀試驗初步結果顯示普克魯胺治療COVID-19患者突出的效果及良好的安全性。公司預期臨牀試驗的最終臨牀研究薄酒將於2021年1月完成。

此前於7月7日,開拓藥業宣佈與Applied Biology,Inc.訂立臨牀試驗研究協議,進行普克魯胺(GT0918)治療新型冠狀病毒肺炎的研究。開拓藥業股價於7月13日股價暴漲超30%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account